JP2018522880A - デングウイルス及び樹状細胞による併用療法のための組成物及び方法 - Google Patents

デングウイルス及び樹状細胞による併用療法のための組成物及び方法 Download PDF

Info

Publication number
JP2018522880A
JP2018522880A JP2017568234A JP2017568234A JP2018522880A JP 2018522880 A JP2018522880 A JP 2018522880A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2018522880 A JP2018522880 A JP 2018522880A
Authority
JP
Japan
Prior art keywords
cancer
subject
cells
dengue virus
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522880A5 (enExample
Inventor
ダブリュ． リデイ，ブルース
ダブリュ． リデイ，ブルース
Original Assignee
プライムヴァックス イミュノ−オンコロジー，インク．
プライムヴァックス イミュノ−オンコロジー，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プライムヴァックス イミュノ−オンコロジー，インク．, プライムヴァックス イミュノ−オンコロジー，インク． filed Critical プライムヴァックス イミュノ−オンコロジー，インク．
Publication of JP2018522880A publication Critical patent/JP2018522880A/ja
Publication of JP2018522880A5 publication Critical patent/JP2018522880A5/ja
Priority to JP2021113634A priority Critical patent/JP2021176862A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
JP2017568234A 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法 Pending JP2018522880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021113634A JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562231351P 2015-07-02 2015-07-02
US62/231,351 2015-07-02
PCT/US2016/040787 WO2017004567A1 (en) 2015-07-02 2016-07-01 Compositions and methods for combination therapy with dengue virus and dendritic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021113634A Division JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2018522880A true JP2018522880A (ja) 2018-08-16
JP2018522880A5 JP2018522880A5 (enExample) 2019-08-08

Family

ID=57609586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568234A Pending JP2018522880A (ja) 2015-07-02 2016-07-01 デングウイルス及び樹状細胞による併用療法のための組成物及び方法
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021113634A Pending JP2021176862A (ja) 2015-07-02 2021-07-08 デングウイルス及び樹状細胞による併用療法のための組成物及び方法

Country Status (8)

Country Link
US (6) US9730989B2 (enExample)
EP (1) EP3316897A4 (enExample)
JP (2) JP2018522880A (enExample)
CN (1) CN107921063A (enExample)
CA (1) CA2991212A1 (enExample)
DE (1) DE202016008300U1 (enExample)
MX (1) MX2018000052A (enExample)
WO (1) WO2017004567A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500847A (ja) * 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
JP2022023061A (ja) * 2015-09-26 2022-02-07 プライムヴァックス イミュノ－オンコロジー，インク． 樹状細胞を産生するための組成物及び方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
EP3638304B1 (en) * 2017-06-12 2024-07-31 Washington University Engineered oncolytic zika virus for use in the treatment of cancer
MX2019015194A (es) * 2017-06-15 2020-08-03 Primevax Immuno Oncology Inc Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048686A (en) * 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer
JP2002504322A (ja) * 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
JP2004507445A (ja) * 2000-02-04 2004-03-11 ライデイ　ブルース　ダブリュ． 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015972A (en) 1905-09-25 1912-01-30 Westinghouse Electric & Mfg Co Electric switch.
US1035755A (en) 1908-07-21 1912-08-13 Glenn S Smith Draftsman's apparatus.
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6511667B1 (en) * 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
CN1191092C (zh) 1999-03-26 2005-03-02 沃尔特里德军事研究院 多价登革病毒疫苗
CA2367590A1 (en) 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
EP1775343A4 (en) 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR20170086700A (ko) * 2005-04-08 2017-07-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
SI2589602T1 (sl) 2006-08-15 2016-08-31 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Office of Technology Transfer Razvoj sestavin cepiva proti virusu denge
US8871211B2 (en) * 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CA2793458A1 (en) 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
JP2014515367A (ja) 2011-05-26 2014-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 不活性化デング熱ウイルスワクチン
EP2543386A1 (en) * 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
TW201402143A (zh) * 2012-06-10 2014-01-16 Inviragen Inc 抗登革熱病毒疫苗之組成物及投藥方法
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
US20180127717A1 (en) 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
EP3316897A4 (en) * 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
EP3541417A4 (en) 2016-11-16 2020-05-27 Primevax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
MX2019015194A (es) 2017-06-15 2020-08-03 Primevax Immuno Oncology Inc Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504322A (ja) * 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
US6048686A (en) * 1998-05-05 2000-04-11 Randy Kyle Brown Hyperthermia and immunotherapy for cancer
JP2004507445A (ja) * 2000-02-04 2004-03-11 ライデイ　ブルース　ダブリュ． 白血病、リンパ腫、及び充実性腫瘍のための温熱療法及び免疫療法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNOTHERAPY, vol. 2, no. 1, JPN6020020792, 2010, pages 57 - 68, ISSN: 0004286368 *
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 13, no. 3, JPN6020020789, 16 January 2015 (2015-01-16), pages 1 - 12, ISSN: 0004286365 *
VACCINE, vol. 26, JPN6020020791, 2008, pages 3197 - 3208, ISSN: 0004286367 *
VIROLOGY, vol. 253, JPN6020020790, 1999, pages 86 - 95, ISSN: 0004286366 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022023061A (ja) * 2015-09-26 2022-02-07 プライムヴァックス イミュノ－オンコロジー，インク． 樹状細胞を産生するための組成物及び方法
JP2020500847A (ja) * 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法

Also Published As

Publication number Publication date
US20170000868A1 (en) 2017-01-05
US9730989B2 (en) 2017-08-15
US9849167B2 (en) 2017-12-26
CA2991212A1 (en) 2017-01-05
US20190046622A1 (en) 2019-02-14
CN107921063A (zh) 2018-04-17
MX2018000052A (es) 2018-05-11
US10159727B2 (en) 2018-12-25
EP3316897A4 (en) 2019-03-13
JP2021176862A (ja) 2021-11-11
US10946080B2 (en) 2021-03-16
EP3316897A1 (en) 2018-05-09
US20180050098A1 (en) 2018-02-22
WO2017004567A1 (en) 2017-01-05
US20170304422A1 (en) 2017-10-26
DE202016008300U1 (de) 2017-07-14
US20190247479A1 (en) 2019-08-15
US20210187086A1 (en) 2021-06-24
US10357553B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
US10946080B2 (en) Compositions and methods for combination therapy with dengue virus and dendritic cells
US20200360497A1 (en) Compositions and methods for producing dendritic cells
US12059443B2 (en) Method for treating cancer using dengue virus serotype 1 (DENV-1)
US12377115B2 (en) Combination immunotherapies for treatment of cancer
US20200121745A1 (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells
CA3028168C (en) Compositions and methods for activating antigen presenting cells with chimeric poliovirus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210310